KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Other Non-Current Liabilities (2016 - 2025)

AbbVie (ABBV) has disclosed Other Non-Current Liabilities for 14 consecutive years, with $32.0 billion as the latest value for Q2 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 51.49% to $32.0 billion in Q2 2025 year-over-year; TTM through Jun 2025 was $32.0 billion, a 51.49% increase, with the full-year FY2024 number at $30.1 billion, up 51.48% from a year prior.
  • Other Non-Current Liabilities was $32.0 billion for Q2 2025 at AbbVie, up from $31.2 billion in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $32.0 billion in Q2 2025 to a low of $12.5 billion in Q1 2021.
  • A 5-year average of $19.4 billion and a median of $18.3 billion in 2023 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: soared 82.5% in 2021, then decreased 2.43% in 2022.
  • AbbVie's Other Non-Current Liabilities stood at $14.9 billion in 2021, then increased by 10.06% to $16.4 billion in 2022, then grew by 21.4% to $19.9 billion in 2023, then surged by 51.48% to $30.1 billion in 2024, then increased by 6.34% to $32.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Other Non-Current Liabilities are $32.0 billion (Q2 2025), $31.2 billion (Q1 2025), and $30.1 billion (Q4 2024).